Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 7Plasma cell 4Breast 3Dermatologic 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Melanoma 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × dinaciclib × Dermatologic × Clear all
NCT00937937 2026-04-29

Dinaciclib in Treating Patients With Stage IV Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
72 enrolled 14 charts
Dermatologic

Melanoma

NCT01026324 2017-04-04

Dinaciclib in Treating Patients With Stage III-IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
12 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡